Abstract
Although the administration of ß2-agonists by inhalation is recommended in the current guidelines for treatment of patients with acute bronchospasm, the large volume spacer that is necessary often is not available on board an ambulance due to space storage problems. Accordingly, an adapter enabling the application of therapeutic aerosols from a metered-dose inhaler (MDI) via a resuscitator bag (Ambu MediBag®) was developed. The aim of this double-blinded, randomised study was to test the clinical efficiency of the Ambu MediBag® (volume: ∼1500 ml) in comparison with the commonly used Volumatic®-Spacer (volume: 750 ml). One hundred patients receiving a bronchodilator response test were treated with MDIs of either 200 μg salbutamol via the Volumatic®-Spacer or 400 μg salbutamol via the Ambu MediBag®. The change of lung function variables was measured by bodyplethysmography before and after drug application. In both groups of 50 patients each, a highly significant reduction of airway resistance was shown after treatment. However, there was no statistically significant difference in lung function variables between the Ambu MediBag® and the Volumatic®-Spacer. From these results, we conclude that the Ambu MediBag® is as effective as Volumatic®-Spacer and might improve preclinical and clinical treatment of acute bronchospasm by inhalation with bronchodilators.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
